rvsv
Vaccineexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 10, 2013 (NCT01859325)
Timeline
Indications
Mechanism of action
- EbolavirusImmunity, active
Ebolavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rvsv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02876328 | Phase 2 | Mar 31, 2017 | Institut National de la Santé Et de la Recherche Médicale, France, National Institute of Allergy and Infectious Diseases (NIAID), Redemption Hospital, The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project, University of London, University of Sierra Leone |
| NCT01859325 | Phase 1 | May 10, 2013 | National Institute of Allergy and Infectious Diseases (NIAID), Profectus BioSciences, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 2 | 2013 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Profectus BioSciences, Inc. | For profit | 1 | 0 | 1 | 2013 |
| Redemption Hospital | Academic/Hospital | 1 | 0 | 1 | 2017 |
| The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Sierra Leone | Academic/Hospital | 1 | 0 | 1 | 2017 |
7 organizations
Page 1 / 1